In vivo gene delivery in the brain using adeno-associated virus-based (AAV) vectors. We have shown that AAV vectors can drive
stable gene expression (at least one year) in the brain with however a variable efficacy and durability. In the globus pallidus, gene
expression es early and efficient whereas in the striatum, a potential target for the treatment of Huntington and Parkinson's
diseases, it  is stable but not efficient. New vectors developed in another theme are currently evaluated.